Search

Your search keyword '"O'Brien, Sarah H."' showing total 394 results
Start Over Author "O'Brien, Sarah H." Language english
394 results on '"O'Brien, Sarah H."'

4. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial

Author

O'Brien, Sarah H, Rodriguez, Vilmarie, Lew, Glen, Newburger, Jane W, Schultz, Corinna L, Orgel, Etan, Derr, Kimberly, Ranalli, Mark A, Esbenshade, Adam J, Hochberg, Jessica, Kang, Hyoung Jin, Dinikina, Yulia, Mills, Donna, Donovan, Mark, Dyme, Joshua L, Favatella, Nicholas A, and Mitchell, Lesley G

Published
2024
Full Text
View/download PDF

14. Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature

Author

Brignardello-Petersen, Romina, El Alayli, Abdallah, Husainat, Nedaa, Kalot, Mohamad, Shahid, Shaneela, Aljabirii, Yazan, Britt, Alec, Alturkmani, Hani, El-Khechen, Hussein, Motaghi, Shahrzad, Roller, John, Dimassi, Ahmad, Abughanimeh, Omar, Madoukh, Bader, Arapshian, Alice, Grow, Jean M., Kouides, Peter, Laffan, Michael, Leebeek, Frank W.G., O'Brien, Sarah H., Tosetto, Alberto, James, Paula D., Connell, Nathan T., Flood, Veronica, and Mustafa, Reem A.

Published
2022
Full Text
View/download PDF

17. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

Author

Connell, Nathan T., Flood, Veronica H., Brignardello-Petersen, Romina, Abdul-Kadir, Rezan, Arapshian, Alice, Couper, Susie, Grow, Jean M., Kouides, Peter, Laffan, Michael, Lavin, Michelle, Leebeek, Frank W.G., O'Brien, Sarah H., Ozelo, Margareth C., Tosetto, Alberto, Weyand, Angela C., James, Paula D., Kalot, Mohamad A., Husainat, Nedaa, and Mustafa, Reem A.

Published
2021
Full Text
View/download PDF

22. Illustrated State‐of‐the‐Art Capsules of the ISTH 2019 Congress in Melbourne, Australia

Author

Ward, Christopher M., Andrews, Robert K., Barco, Stefano, Battinelli, E.M., Boilard, Eric, Bos, Mettine H.A., Chicanne, G., Chuansumrit, Ampaiwan, Conway, Edward M., Curry, N., Cutler, Daniel, Danese, Elisa, De Meyer, Simon F., Del Rio, Jose M., Despotovic, Jenny, Di Paola, Jorge, Eikelboom, John, Emsley, Jonas, Eto, Koji, Fijnvandraat, Karin, Flaumenhaft, Robert, Flick, Matthew, Fuchs, Tobias A., Gomez, Keith, Goto, Shinya, Hamilton, Justin R., Hitchcock, Ian S., Jenne, Craig N., Johnsen, Jill M., Ju, Lining A., Le Gal, Grégoire, Levade, M., Lip, Gregory Y.H., Luyendyk, Jim, Maas, Coen, Magnusson, Maria, Mangin, Pierre, Mast, Alan, McLintock, Claire, Miranda, Sébastien, Nathwani, Amit, Ni, Heyu, Áinle, Fionnuala N., Nilsson, Susie, Ny, Tor, O’Brien, Sarah H., O’Donnell, James S., Payrastre, B., Peter, Karlheinz, Rak, Janusz, Randi, Anna M., Rauova, Lubica, Reinhardt, Christoph, Rodger, Marc, Rondina, Matthew, Schreiber, Karen, Severin, S., Shima, Midori, Spyropoulos, Alex, Stanworth, S.J., Suzuki‐Inoue, Katsue, Thomas, Moumneh, Tsukiji, Nagaharu, Urano, Tetsumei, Valet, C., Vanhoorelbeke, Karen, Verhamme, Peter, Weitz, Jeffrey, Wolberg, Alisa, Zentner, Dominica, and Zhu, Cheng

Published
2019
Full Text
View/download PDF

28. Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap.

Author

Davila, Jennifer, O'Brien, Sarah H., Mitchell, William B., and Manwani, Deepa

Subjects
*SICKLE cell anemia, *EVIDENCE gaps, *CELL populations, *THROMBOEMBOLISM, *HEMOLYTIC anemia
Abstract

Summary: Sickle cell disease (SCD) arises from beta‐globin gene mutations, with global estimates indicating around 500 000 affected neonates in 2021. In the United States, it is considered rare, impacting fewer than 200 000 individuals. The key pathogenic flaw lies in mutant haemoglobin S, prone to polymerization under low oxygen conditions, causing erythrocytes to adopt a sickled shape. This leads to complications like vascular occlusion, haemolytic anaemia, inflammation and organ damage. Beyond erythrocyte abnormalities however, there is a body of literature highlighting the hypercoagulable state that is likely a contributor to many of the complications we see in SCD. The persistent activation of the coagulation cascade results in thromboembolic events, notably venous thromboembolism (VTE) which is independently associated with increased mortality in both adults and children with SCD. While the increased risk of VTE in the SCD population seems well established, there is a lack of guidelines for thromboprophylaxis in this population. This Wider Perspective will describe the hypercoagulable state and increased thrombosis risk in the SCD population, as well as advocate for the development of evidence‐based guidelines to aid in the prevention of VTE in SCD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism

Author

Monagle, Paul, Cuello, Carlos A., Augustine, Caitlin, Bonduel, Mariana, Brandão, Leonardo R., Capman, Tammy, Chan, Anthony K.C., Hanson, Sheila, Male, Christoph, Meerpohl, Joerg, Newall, Fiona, O'Brien, Sarah H., Raffini, Leslie, van Ommen, Heleen, Wiernikowski, John, Williams, Suzan, Bhatt, Meha, Riva, John J., Roldan, Yetiani, Schwab, Nicole, Mustafa, Reem A., and Vesely, Sara K.

Published
2018
Full Text
View/download PDF

38. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study

Author

Creary, Susan, Chisolm, Deena, Stanek, Joseph, Hankins, Jane, and O'Brien, Sarah H

Subjects
Information technology, T58.5-58.64, Public aspects of medicine, RA1-1270
Abstract

BackgroundHydroxyurea is a disease-modifying medication for patients with sickle cell disease (SCD). Despite demonstrated efficacy, hydroxyurea nonadherence in clinical practice is common and results in worse health outcomes for nonadherent patients. Mobile Directly Observed Therapy (Mobile DOT) is a pilot-tested, electronic, multidimensional hydroxyurea adherence intervention for children with SCD. Mobile DOT includes sending daily text message reminders to patients to take hydroxyurea, patients recording and sending daily videos that capture their hydroxyurea administrations for the research team to review and track adherence, providing personalized feedback to patients about their adherence, and providing small monetary incentives to patients if they achieve high hydroxyurea adherence. ObjectiveThis study aimed to determine if Mobile DOT increases hydroxyurea adherence in children with SCD and to explore its impact on hematologic and clinical outcomes. MethodsThis was a single-arm, 6-month intervention study of patients with SCD on hydroxyurea who were aged ≤19 years and reported having access to an electronic device. Participants’ hydroxyurea adherence when they received Mobile DOT was compared with their adherence 6 months before and after receiving Mobile DOT. Participants’ medication possession ratio (MPR) was calculated from their pharmacy dispensing records and was used to measure adherence. Laboratory and clinical outcomes were abstracted from participants’ electronic medical records. Infrequently hospitalized patients who received at least 160 days of the intervention were considered to be engaged participants. ResultsOf 91 patients who were approached, 55 enrolled and 34 engaged with Mobile DOT. The median age of the engaged participants was 10 years (range 2-18.8 years), and 21 (62%, 21/34) participants were male, 28 (82%, 21/34) had hemoglobin SS SCD, and 19 (56%, 19/34) were prescribed hydroxyurea for at least a year before enrollment. With Mobile DOT, engaged participants’ median MPR increased from 61.7% to 84.4% (P

Published
2019
Full Text
View/download PDF

44. Five hematologic tests and treatments to question

Author

Hicks, Lisa K., Bering, Harriet, Carson, Kenneth R., Haynes, Adam E., Kleinerman, Judith, Kukreti, Vishal, Ma, Alice, Mueller, Brigitta U., O’Brien, Sarah H., Panepinto, Julie A., Pasquini, Marcelo C., Rajasekhar, Anita, Sarode, Ravi, and Wood, William A.

Published
2014
Full Text
View/download PDF

45. Assessing Bleeding Symptoms in Pediatric Patients With Generalized Joint Hypermobility.

Author

Kendel, Nicole E., Stanek, Joseph R., Thomas, Bethanne B., Ardoin, Stacy P., and O'Brien, Sarah H.

Subjects
JOINT hypermobility, CHILD patients, CHILDREN'S hospitals, HEMORRHAGE, SYMPTOMS
Abstract

Objective: To assess bleeding symptoms in patients with generalized/benign joint hypermobility (GJH), compare bleeding scores to healthy historical pediatric controls, and determine whether a correlation exists between Beighton scores and bleeding scores. Methods: Patients with GJH ages 6–21 years seen by the rheumatology department at Nationwide Children's Hospital in Columbus, Ohio were eligible. Participants/guardians completed the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool, a validated questionnaire defining the presence, severity, and frequency of bleeding symptoms. Scores of ≥3 have been associated with an underlying bleeding disorder in pediatric patients. Results: Eighty‐one patients agreed to participate. The median age was 13 years (interquartile range 10–16 years), and the mean Beighton score was 6.3 (range 4–9). Commonly observed bleeding symptoms were oral bleeding (74%), easy bruising (59%), and bleeding with minor wounds (42%). Mean and median bleeding scores were 5.2 and 4, respectively, and were significantly higher than reported bleeding scores in pediatric controls, defined as those without bleeding symptoms or a previously diagnosed bleeding disorder (P < 0.001). Although 75% of patients (95% confidence interval 64–84) had an abnormal bleeding score, only 12.3% were previously assessed by hematology for bleeding symptoms. Among patients with GJH, higher Beighton scores were not associated with higher bleeding scores (Spearman's correlation –0.08). Conclusion: In a cohort of pediatric patients with GJH, three‐fourths of participants had abnormal bleeding scores, with the mean bleeding score significantly elevated compared to healthy controls. We propose that screening for bleeding symptoms be integrated into routine care for GJH patients, with referral to hematology for patients with bleeding concerns. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results